View in EDS

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).

Saved in:
Bibliographic Details
Title: A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).
Authors: Berry-Kravis E; Departments of Pediatrics and Neurological Sciences, Rush University Medical Center, Chicago, IL, USA., Hagerman R; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California-Davis Medical Center, Sacramento, CA, USA.; Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA., Budimirovic D; Departments of Psychiatry and Child Psychiatry, Fragile X Clinic, Kennedy Krieger Institute/the Johns Hopkins Medical Institutions, Baltimore, MD, USA.; Department of Psychiatry & Behavioral Sciences-Child Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA., Erickson C; Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA., Heussler H; Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children's Health Queensland, Brisbane, Australia.; Centre for Child Health Research, University of Queensland, Brisbane, Australia., Tartaglia N; Department of Pediatrics, Developmental Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, USA., Cohen J; Fragile X Alliance Inc, North Caulfield, VIC, Australia.; Centre for Developmental Disability Health Victoria, Monash University, Clayton, VIC, Australia., Tassone F; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California-Davis Medical Center, Sacramento, CA, USA.; Department of Biochemistry and Molecular Medicine, School of Medicine, University of California-Davis, Sacramento, CA, USA., Dobbins T; The Griesser Group, Conshohocken, PA, USA., Merikle E; Labcorp Drug Development, Durham, NC, USA., Sebree T; Zynerba Pharmaceuticals Inc., Devon, PA, USA., Tich N; Zynerba Pharmaceuticals Inc., Devon, PA, USA., Palumbo JM; Zynerba Pharmaceuticals Inc., Devon, PA, USA., O'Quinn S; Zynerba Pharmaceuticals Inc., Devon, PA, USA. Oquinns@Zynerba.com.
Source: Journal of neurodevelopmental disorders [J Neurodev Disord] 2022 Nov 25; Vol. 14 (1), pp. 56. Date of Electronic Publication: 2022 Nov 25.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101483832 Publication Model: Electronic Cited Medium: Internet ISSN: 1866-1955 (Electronic) Linking ISSN: 18661947 NLM ISO Abbreviation: J Neurodev Disord Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36434514
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Berry-Kravis+E%22">Berry-Kravis E</searchLink>; Departments of Pediatrics and Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Hagerman+R%22">Hagerman R</searchLink>; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California-Davis Medical Center, Sacramento, CA, USA.; Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA.<br /><searchLink fieldCode="AU" term="%22Budimirovic+D%22">Budimirovic D</searchLink>; Departments of Psychiatry and Child Psychiatry, Fragile X Clinic, Kennedy Krieger Institute/the Johns Hopkins Medical Institutions, Baltimore, MD, USA.; Department of Psychiatry & Behavioral Sciences-Child Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Erickson+C%22">Erickson C</searchLink>; Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA.<br /><searchLink fieldCode="AU" term="%22Heussler+H%22">Heussler H</searchLink>; Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children's Health Queensland, Brisbane, Australia.; Centre for Child Health Research, University of Queensland, Brisbane, Australia.<br /><searchLink fieldCode="AU" term="%22Tartaglia+N%22">Tartaglia N</searchLink>; Department of Pediatrics, Developmental Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22Cohen+J%22">Cohen J</searchLink>; Fragile X Alliance Inc, North Caulfield, VIC, Australia.; Centre for Developmental Disability Health Victoria, Monash University, Clayton, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Tassone+F%22">Tassone F</searchLink>; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California-Davis Medical Center, Sacramento, CA, USA.; Department of Biochemistry and Molecular Medicine, School of Medicine, University of California-Davis, Sacramento, CA, USA.<br /><searchLink fieldCode="AU" term="%22Dobbins+T%22">Dobbins T</searchLink>; The Griesser Group, Conshohocken, PA, USA.<br /><searchLink fieldCode="AU" term="%22Merikle+E%22">Merikle E</searchLink>; Labcorp Drug Development, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Sebree+T%22">Sebree T</searchLink>; Zynerba Pharmaceuticals Inc., Devon, PA, USA.<br /><searchLink fieldCode="AU" term="%22Tich+N%22">Tich N</searchLink>; Zynerba Pharmaceuticals Inc., Devon, PA, USA.<br /><searchLink fieldCode="AU" term="%22Palumbo+JM%22">Palumbo JM</searchLink>; Zynerba Pharmaceuticals Inc., Devon, PA, USA.<br /><searchLink fieldCode="AU" term="%22O'Quinn+S%22">O'Quinn S</searchLink>; Zynerba Pharmaceuticals Inc., Devon, PA, USA. Oquinns@Zynerba.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101483832%22">Journal of neurodevelopmental disorders</searchLink> [J Neurodev Disord] 2022 Nov 25; Vol. 14 (1), pp. 56. <i>Date of Electronic Publication: </i>2022 Nov 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101483832 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1866-1955 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2218661947%22">18661947 </searchLink><i>NLM ISO Abbreviation: </i>J Neurodev Disord <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36434514
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s11689-022-09466-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 56
    Titles:
      – TitleFull: A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Berry-Kravis E
      – PersonEntity:
          Name:
            NameFull: Hagerman R
      – PersonEntity:
          Name:
            NameFull: Budimirovic D
      – PersonEntity:
          Name:
            NameFull: Erickson C
      – PersonEntity:
          Name:
            NameFull: Heussler H
      – PersonEntity:
          Name:
            NameFull: Tartaglia N
      – PersonEntity:
          Name:
            NameFull: Cohen J
      – PersonEntity:
          Name:
            NameFull: Tassone F
      – PersonEntity:
          Name:
            NameFull: Dobbins T
      – PersonEntity:
          Name:
            NameFull: Merikle E
      – PersonEntity:
          Name:
            NameFull: Sebree T
      – PersonEntity:
          Name:
            NameFull: Tich N
      – PersonEntity:
          Name:
            NameFull: Palumbo JM
      – PersonEntity:
          Name:
            NameFull: O'Quinn S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 11
              Text: 2022 Nov 25
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1866-1955
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of neurodevelopmental disorders
              Type: main
ResultId 1